Abo Zygosity, But Not Secretor Or Fc Receptor Status, Is A Significant Risk Factor For Ivig-Associated Hemolysis

TO THE EDITOR:Although frequently effective[1][1],[2][2] and usually benign, high-dose (2 g/kg) intravenous immunoglobulin (IVIG) therapy can result in marked red blood cell (RBC) hemolysis, which in some cases is life threatening in severity.[3][3][⇓][4]-[5][5] The mechanism by which this